<DOC>
	<DOCNO>NCT00352950</DOCNO>
	<brief_summary>To determine dose schedule sirolimus give combination panitumumab adult subject Stage IIIB/IV NSCLC</brief_summary>
	<brief_title>Safety Evaluation Panitumumab Sirolimus Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically cytologicallyconfirmed diagnosis stage IIIB IV NonSmall Cell Lung Cancer Received one prior treatment ( include radiation ) Measurable disease per Response Evaluation Criteria Solid Tumors Group ( RECIST ) guideline Life expectancy ≥ 4 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic , renal hepatic function Serumfasting cholesterol ≤ 300 mg/dL Serumfasting triglycerides ≤ 2.5 X ULN Brain metastases require treatment History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis baseline Systemic chemotherapy , radiotherapy , hormonal therapy immunotherapy within 30 day enrollment Prior epidermal growth factor receptor target agent exception small molecule EGFr tyrosine kinase inhibitor Prior antitumor therapy include prior experimental agent approve antitumor small molecule biologics short serum halflife ( le 1 week ) within 30 day enrollment , prior experimental approve proteins/antibodies longer serum halflife within 6 week enrollment Prior therapy sirolimus , sirolimus analog Immunosuppressive agent within 28 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>NSCLC , Lung cancer</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>mTOR</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>